The role of the complement system in age-related macular degeneration;Bedeutung des komplementsystems für die altersabhängige makuladegeneration

Deutsches Arzteblatt International

Volumn 111, Issue 8, 2014, Pages 133-138

  Weber, Bernhard H F ^a   Charbel Issa, Peter ^b   Pauly, Diana ^a   Herrmann, Philipp ^b,c   Grassmann, Felix ^a   Holz, Frank G ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR D; LAMPALIZUMAB; COMPLEMENT; GENETIC MARKER;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPLEMENT SYSTEM; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC SCREENING; GEOGRAPHIC ATROPHY; HEREDITY; HUMAN; INNATE IMMUNITY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RETINA MACULA AGE RELATED DEGENERATION; SENESCENCE; SIGNAL TRANSDUCTION; SMOKING; SYSTEMATIC REVIEW; AGE DISTRIBUTION; AGED; COMORBIDITY; FEMALE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INCIDENCE; MACULAR DEGENERATION; MALE; META ANALYSIS; MIDDLE AGED; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; VISION DISORDERS;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COMORBIDITY; COMPLEMENT SYSTEM PROTEINS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; VISION DISORDERS;

EID: 84899540510     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0133     Document Type: Article

References (39)

1. Ho L, van Leeuwen R, de Jong PTVM, Vingerling JR, Klaver CCW: Epidemiologie der AMD. Altersabhängige Makuladegeneration. 3rd edition. Berlin, Heidelberg: Springer 2011: 3-31.
2. Smith W, Assink J, Klein R, et al.: Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001; 108: 697-704. (Pubitemid 32238465)
3. Finger RP, Fimmers R, Holz FG, Scholl HPN: Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Ophthalmol Vis Sci 2011; 52: 4381-9.
4. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY: Age-related macular degeneration. Lancet 2012; 379: 1728-38.
5. Evans JR: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. The Cochrane database of systematic reviews 2006; (2): CD000254.
6. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthal 2001; 119: 1417-36.
7. Age-Related Eye Disease Study 2 Research Group.: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-15.
8. Klein EA, Thompson IM, Tangen CM, et al.: Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
9. Finger RP, Bertram B, Wolfram C, Holz FG: Blindness and visual impairment in Germany: a slight fall in prevalence. Dtsch Arztebl Int 2012; 109: 484-9.
10. Schmitz-Valckenberg S, Mössner A, Fleckenstein M, Wiedemann P, Holz FG: [Therapy approaches for geographic atrophy]. Ophthalmologe 2010; 107: 1016-9.
11. Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M: Geographic atrophy: clinical features and potential future therapeutic approaches. Ophthlamology 2014; epub ahead of print.
12. Herrmann P, Holz FG, Charbel Issa P: Ätiologie und Pathogenese der altersabhängigen Makuladegeneration. Ophthalmologe 2013; 110: 377-87.
13. Chakravarthy U, Wong TY, Fletcher A, et al.: Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
14. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC: The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthal 2005; 123: 321-7. (Pubitemid 41007575)
15. Fritsche LG, Chen W, Schu M, et al.: Seven new loci associated with age-related macular degeneration. Nat Genet 2013; 45: 433-9, 439e1-2.
16. Edwards AO, Ritter R, Abel KJ, et al.: Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4. (Pubitemid 40530082)
17. Haines JL, Hauser M, Schmidt S, et al.: Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419-21. (Pubitemid 40530081)
18. Klein RJ, Zeiss C, Chew EY, et al.: Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-9. (Pubitemid 40530070)
19. Jakobsdottir J, Conley YP, Weeks DE, et al.: Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005; 77: 389-407. (Pubitemid 41192646)
20. Rivera A, Fisher SA, Fritsche LG, et al.: Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005; 14: 3227-36. (Pubitemid 41631297)
21. Grassmann F, Fritsche LG, Keilhauer CN, Heid IM, Weber BHF: Modelling the genetic risk in age-related macular degeneration. PLoS One 2012; 7: e37979.
22. Spencer KL, Olson LM, Schnetz-Boutaud N, et al.: Using genetic variation and environmental risk factor data to identify individuals at high risk for age-related macular degeneration. PLoS One 2011; 6: e17784.
23. Gibson J, Cree A, Collins A, Lotery A, Ennis S: Determination of a gene and environment risk model for age-related macular degeneration. Br J Ophthalmol 2010; 94: 1382-7.
24. Seddon JM, Reynolds R, Maller J, et al.: Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci 2009; 50: 2044-53.
25. Raychaudhuri S, Iartchouk O, Chin K, et al.: A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet 2011; 43: 1232-6.
26. th edition. Stuttgart, New York: Thieme Verlag 2011: 347-62.
27. Burton H, Cole T, Lucassen AM: Genomic medicine: challenges and opportunities for physicians. Clin Med 2012; 12: 416-9.
28. Offit K: Personalized medicine: new genomics, old lessons. Hum Genet 2011; 130: 3-14.
29. Guttmacher AE, McGuire AL, Ponder B, Stefánsson K: Personalized genomic information: preparing for the future of genetic medicine. Nat Rev Genet 2010; 11: 161-5.
30. Despriet DDG, Klaver CCW, Witteman JCM, et al.: Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006; 296: 301-9. (Pubitemid 44079314)
31. Seddon JM, Francis PJ, George S, et al.: Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 2007; 297: 1793-800. (Pubitemid 46658648)
32. Baird PN, Robman LD, Richardson AJ, et al.: Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. Hum Mol Genet 2008; 17: 1299-305. (Pubitemid 351566966)
33. Francis PJ, Hamon SC, Ott J, Weleber RG, Klein ML: Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J Med Genet 2009; 46: 300-7.
34. Ho L, van Leeuwen R, Witteman JCM, et al.: Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and ù-3 fatty acids: the Rotterdam study. Arch Ophthal 2011; 129: 758-66.
35. Magnusson KP, Duan S, Sigurdsson H, et al.: CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006; 3: e5.
36. Farwick A, Dasch B, Weber BHF, et al.: Variations in five genes and the severity of age-related macular degeneration: results from the Muenster aging and retina study. Eye (Lond) 2009; 23: 2238-44.
37. Scholl HPN, Fleckenstein M, Fritsche LG, et al.: CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One 2009; 4: e7418.
38. Hagstrom SA, Ying G-S, Pauer GJT, et al.: Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT). Ophthalmology 2013; 120: 593-9.
39. Khandhadia S, Cipriani V, Yates JRW, Lotery AJ: Age-related macular degeneration and the complement system. Immunobiology 2012; 217: 127-46.